The unique fluorescence properties of quantum dots (QDs), particulary high brightness and photostability, make them ideal probes for tracking proteins in live cells using real-time visualization. We have shown that QDs conjugated to Epidermal Growth Factor (EGF) act as functional ligands for their receptor, erbB1. Here, we describe protocols for (a) conjugation of streptavidin-QDs to biotinylated ligand, (b) formation of ligand-QD-receptor complexes and (c) quantification of binding and internalization of receptor complex using both high-resolution fluorescence microscopy and flow cytometry.
Introduction
The erbB family of receptor tyrosine kinases (RTK) includes erbB1 (the classical epidermal growth factor receptor, EGFR), erbB2, erbB3 and erbB4 (1). Binding of EGF to the extracellular domain of erbB1 leads to auto-and transactivation of cytoplasmic protein kinase domains in response to the formation (3) or reorientation (4-6) of homo-and heteroassociated RTK monomers. This activation of the receptor initiates signaling cascades, which control a variety of cellular processes such as DNA replication and division (1,2). ErbB1 activation results in clathrin-mediated endocytosis via coated pits, covalent modification of the receptor, and endosomal trafficking resulting in both down-regulation through proteosomal degradation and recycling to the cell membrane. The proper function of erbB1 in the cell is critical, given that overexpression or mutations of the erbB1 are implicated in many types of cancer (1,7).
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We have shown that QDs conjugated to EGF act as functional ligands for erbB1, and that their unique fluorescence properties provide the means for prolonged real-time visualization of the multiple steps in signaling mechanisms in living cells (8) . In this chapter we outline procedures for binding biotinylated ligands to commercial streptavidin conjugated quantum dots, for specific labeling of growth factor receptors with these ligands and for quantitative measurements of the receptor complexes by both fluorescence microscopy and flow cytometry.
Materials
1. Phosphate buffered saline (PBS): 137 mM NaCl, 2.7 mM KCl, 7.9 mM Na 2 HPO 4 11. Trypsin solution for releasing adherent cells from their substrates: sterile solution of 0.5 mg/ml trypsin in PBS containing 1 mM EDTA.
12. Acid wash buffer: 0.5 M NaCl, 0.1 M Glycine-HCl, pH 2.5. 
Purification of ligand-QD conjugates
After the ligand-QD complex is formed, unbound ligands that are smaller than the QDs can be removed from the conjugate by passing the QDs through a size exclusion column. For SAvQDs described above, Sephadex G-25 medium grade gel filtration is recommended; the SAvQDs will elute in the void volume. Use a 1: 20 ratio of sample to column volume for good separation.
Spin columns can be used for sample volumes of 50 µl or less.
1. Swell and pour the Sephadex according to the manufacturer's instructions.
2. Equilibrate the column in PBS by washing with at least 3 column volumes.
3. Allow the buffer to just enter the top of the gel bed before adding the sample. Avoid air bubbles.
4. Add the sample to the top of the gel bed, allow the sample to enter the gel and add PBS to elute the sample. 
Plating cells

Coverslips and coverslip chambers
Logarithmically growing cells are replated in complete culture medium at the appropriate densities one or two days prior to the experiment. In the case of experiments with growth factor receptors, the cells are serum-starved for 16 -24 h prior to the experiment to reduce signaling induced by the serum in the medium.
Labeling cell surface receptors with preformed ligand-QD complex
1. Wash cells once with Tyrode's plus and maintain in this buffer for the experiment. 5. Start imaging.
Labeling cell surface receptors in a two-step procedure
In some situations the preformed complex may not be functional or the system may not respond properly with the preformed complex due to (a) steric hindrance by the SAvQD during 7. For snapshots of the behavior of the ligand-QD complex over time, incubate coverslips at the appropriate temperatures and times and fix in 4% paraformaldehyde for 15 min on ice to prevent redistribution of the QDs. After fixation, wash the coverslips with Trissaline buffer for 10 min several times and mount in PBS for microscopy.
In vivo visualization and quantitation of ligand-QD binding by fluorescence confocal microscopy
Binding plot for ligand-QD to cells expressing a GFP membrane protein (may be the ligandbinding protein or another membrane protein simply used as a marker).
1. Grow cells in 8-well LabTek chambers as described above. 
Two-color QD "chase" experiment
Multicolor EGF-QDs may be used to track endocytosis of the receptor-ligand complex and to follow subsequent steps in time. Two different colors of ligand-QDs are delivered sequentially.
(An example of this data may be found in a color image included only on the CD ROM copy of this chapter, Figure S1 
Binding of streptavidin-coated quantum dots to cells labeled with different molar ratios of EGF and biotin-EGF
Results of the previous experiments showed that EGF-QD binds to a saturable binding site on the surface of A431 cells. Strong evidence for specific binding is provided by competitive inhibition by another ligand. Activation of erbB1 requires the binding of two EGF molecules to a dimer of erbB1 receptor (3, 10) . The relatively large size of quantum dots requires one to show unambiguously that the ligand-QD is functional. Furthermore, if erbB1 molecules are at high density on the cell surface of A431 cells, a bound quantum dot may sterically hinder binding to a neighboring receptor. To rule out size or steric hindrance by the QDs, we labeled cells with different molar ratios of EGF and biotinylated-EGF, followed by SAvQD and determined whether the fluorescence intensities of the samples were linearly proportional to the molar fraction of biotin-EGF. The higher the molar fraction of biotinylated-EGF, the higher the probability of finding two biotinylated-EGF molecules close to each other, e.g. binding to two 12/18 erbB1 proteins in a dimer. This would result in leveling off of the fluorescence intensity curve at high biotin-EGF concentrations. The fact that we found a strictly linear relationship implies that binding of streptavidin-coated quantum dots is not sterically limited (Fig. 2 ).
1. Trypsinize A431 cells and resuspend in PBS/BSA at a density of 2 ·10 6 /mL. Store on ice (see Note 4).
2. Prepare 100 nM stock solutions of biotin-EGF and EGF in PBS/BSA. Keep the solutions on ice.
3. Prepare a 20 nM stock solution of SAvQD in PBS/BSA and store on ice.
4. Prepare a series of samples (total volume of each is 50 µL) in which the molar ratio of biotin-EGF changes from 0 to 100 %, e.g. 0, 12.5, 25, 37.5, 50, 62.5, 75, 87.5, 100%).
The total concentration of EGF (biotinylated+non-biotinylated) is 100 nM in each sample. 8. Without washing, measure the sample intensities using a flow cytometer.
Quantitative measurement of EGF-QD internalization
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Although microscopy experiments can measure the internalization of ligand-QD in a qualitative or semi-quantitative manner with subcellular resolution, flow cytometry is indispensable for obtaining a quantitative description of the process.
1. Couple Biotin-EGF to SAvQDs at a molar ratio of 6:1 as described in section 3.1.2.
2. Trypsinize A431 cells and resuspended at a density of 10 6 /mL in Tyrode's buffer plus.
3. Add 1 nM EGF-QD to the sample and incubate at 37 o C with regular shaking.
4. Take 600 µL samples at 0, 5, 10, 20 and 30 min.
5. Add 5 mL of acid wash buffer to half of the sample, and incubate on ice for 5 min.
6. Wash with a large excess of PBS and resuspend cells in 300 µL Tyrode's plus. 
